At J.M. Kyriakidis SA we serve public health. Our purpose is to help organizations and healthcare professionals provide the highest quality health services.

+30 210 6072700
info@jmkyriakidis.gr
Garittou & Acherontos 1, 15343 Agia Paraskevi

Agia Paraskevi 15343
+30 210-6072700
Working Hours Monday-Friday 08:30-16:30
Image Alt

Προϊόντα

LUMIPULSE® G1200

The LUMIPULSE G1200 is a robust mid-sized fully automated immunoassay instrument from the already widely successful LUMIPULSE G series.

SKU: lumipulse-g1200
Categories: , ,

Description

LUMIPULSE® G1200

 
Lumipulse G CLIA analyzer cartridge close up
LUMIPULSE G1200 fully automated CLEIA analyzer with sample kit package

The LUMIPULSE G1200 is a robust mid-sized fully automated immunoassay instrument from the already widely successful LUMIPULSE G series.

The LUMIPULSE G1200 uses a unique mono test cartridge concept and among many other features performs a true throughput of 120 tests per hour providing outstanding flexibility and easy handling in hospitals and clinical Laboratories.

Test Menu

https://www.fujirebio.com/en/products-solutions/kits-for-fully-automated-testing

 

Specifications

  1. Runs 120 tests per hour, giving first results in just 3o minutes and then every minute thereafter
  2. The reagents are in mono test format, ready to use
  3. Random Access and continuous loading
  4. Long calibration stability
  5. Single-use tips to minimize any risks of contamination
  6. Long on-board reagent stability
  7. Bi-directional connection to LIS.

COVID-19

For in vitro diagnostic (IVD) use with the Lumipulse G system for detection and quantitative measurement of SARS-CoV-2 nucleocapsid protein antigen in human nasopharyngeal swab or saliva. As a diagnostic tool for the confirmation of a SARS-CoV-2 infection.

The assay utilises proven CLEIA (chemiluminescent enzyme immunoassay) technology with results that are available in up to 35 minutes.

CE marked

Neurogeneration Menu

Pioneers in early and reliable Alzheimer’s disease diagnostics

Cerebrospinal fluid (CSF) biomarkers, developed first by Fujirebio more than 25 years ago, have evolved over time from research biomarkers to specialized diagnostic testing, and from usage by early adopters to a widespread implementation as routine testing today.

Diagnosis based on CSF samples allows the detection of four proteins; two forms of amyloid (Aβ1-42 and Aβ1-40) proteins and two forms of Tau (Total Tau and phospho-Tau) proteins. If a patient has Alzheimer’s disease, then these proteins will be present in abnormally low (Aβ1-42 and Aβ1-42/Aβ1-40 ratio) and high (Total Tau and phospho-Tau) levels. The Aβ1-42 protein levels will even be low before the symptoms of the disease start to show.

Related products